HUTCHMED (China) Limited (HKG:0013)
23.76
-0.70 (-2.86%)
Oct 17, 2025, 4:08 PM HKT
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $277.68 million USD in the half year ending June 30, 2025, a decrease of -47.89%. This brings the company's revenue in the last twelve months to $602.2 million, down -1.41% year-over-year. In the year 2024, HUTCHMED (China) had annual revenue of $630.2 million, down -24.80%.
Revenue (ttm)
$602.20M
Revenue Growth
-1.41%
P/S Ratio
4.16
Revenue / Employee
$332.52K
Employees
1,811
Market Cap
19.67B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
JD Health International | 71.34B |
BeOne Medicines AG | 35.81B |
Sino Biopharmaceutical | 33.49B |
Alibaba Health Information Technology | 32.81B |
CSPC Pharmaceutical Group | 28.49B |
WuXi Biologics | 21.98B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |
HUTCHMED (China) News
- 4 days ago - HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - GlobeNewsWire
- 5 days ago - HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewsWire
- 16 days ago - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 - GlobeNewsWire
- 25 days ago - HCM: Morgan Stanley Downgrades Hutchmed (China) with Price Target Cut | HCM Stock News - GuruFocus
- 5 weeks ago - Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 - GlobeNewsWire
- 6 weeks ago - HUTCHMED (China) Ltd (HCM) to Present New Data at Major Oncology Conferences | HCM stock news - GuruFocus
- 6 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer ... - GuruFocus
- 6 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 - GlobeNewsWire